A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies
Phase 1
20 Years
75 Years
20 Years
75 Years
Not Enrolling
Both
Advanced Solid Tumor
Both
Advanced Solid Tumor
Trial Information
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies
Inclusion Criteria:
- advanced solid tumors
- life expectancy is 12 weeks or longer
Exclusion Criteria:
- patient with uncontrolled brain metastases
- patient with inappropriate laboratory test values
- patient with poorly controlled hypertension
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and tolerability
Outcome Time Frame:
Assessed at each visit for 4 weeks
Safety Issue:
No
Principal Investigator
Jane Robertson
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
D8480C00023
NCT ID:
NCT00503477
Start Date:
October 2005
Completion Date:
January 2009
Related Keywords:
- Advanced Solid Tumor
- Japan
- Phase I
- solid tumor
- AZD2171
- Neoplasms
Name | Location |
|---|
